MedTrace Logo

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

NCT02912754 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-03-13

No results posted yet for this study

Summary

This study involves adding the kinase inhibitor Ruxolitinib to Ibrutinib to treat Chronic Lymphocytic Leukemia (CLL).

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG

ruxolitinib

ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle

DRUG

ibrutinib

patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • David E Spaner, MD · Sunnybrook Odette Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-31
Primary Completion
2018-12-31
Completion
2019-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02912754 on ClinicalTrials.gov